Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parsabiv

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Eligible patients will now be able to access the treatment through the NHS in England

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

- PMLiVE

Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

Amgen and Plexium announce new research collaboration worth over $500m

The two companies will work to identify and develop new treatments for cancer and other serious diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links